Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. Among authors: spelman l. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.
Patterns and cost of care according to keratinocyte cancer risk stratification in a volunteer population screening clinic: Real-world data from the TRoPICS study.
Lee RC, Liyanage U, Fry K, Brown S, von Schuckmann L, Spelman L, Soyer HP, Neale RE, Gordon LG, Whiteman DC, Olsen CM, Janda M, Khosrotehrani K. Lee RC, et al. Among authors: spelman l. Australas J Dermatol. 2023 Aug;64(3):389-396. doi: 10.1111/ajd.14054. Epub 2023 Apr 24. Australas J Dermatol. 2023. PMID: 37092598 Free PMC article.
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A. Lebwohl M, et al. Among authors: spelman l. N Engl J Med. 2015 Oct;373(14):1318-28. doi: 10.1056/NEJMoa1503824. N Engl J Med. 2015. PMID: 26422722 Free article. Clinical Trial.
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.
Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Narbutt J, Philipp S, Spelman L, Weglowska J, Zhang N, Strober B. Papp K, et al. Among authors: spelman l. J Am Acad Dermatol. 2017 Jun;76(6):1093-1102. doi: 10.1016/j.jaad.2016.12.014. Epub 2017 Mar 11. J Am Acad Dermatol. 2017. PMID: 28291552 Free article. Clinical Trial.
Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.
Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B. Papp K, et al. Among authors: spelman l. Br J Dermatol. 2017 Dec;177(6):1562-1574. doi: 10.1111/bjd.15857. Epub 2017 Dec 1. Br J Dermatol. 2017. PMID: 28755394 Clinical Trial.
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, King BA, Thyssen JP, Silverberg JI, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman-Yassky E, Beck LA, Janes JM, DeLozier AM, Gamalo M, Brinker DR, Cardillo T, Nunes FP, Paller AS, Wollenberg A, Reich K. Simpson EL, et al. Among authors: spelman l. Br J Dermatol. 2020 Aug;183(2):242-255. doi: 10.1111/bjd.18898. Epub 2020 Mar 5. Br J Dermatol. 2020. PMID: 31995838
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.
Gordon KB, Reich K, Crowley JJ, Korman NJ, Murphy FT, Poulin Y, Spelman L, Yamauchi PS, Mendelsohn AM, Parno J, Rozzo SJ, Ellis CN. Gordon KB, et al. Among authors: spelman l. J Dermatolog Treat. 2022 Feb;33(1):219-228. doi: 10.1080/09546634.2020.1747590. Epub 2020 Apr 30. J Dermatolog Treat. 2022. PMID: 32349565 Clinical Trial.
89 results